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Sofia Malyutina6,7, Laila A. Hopstock5, Olena Iakunchykova5, Yuri Nikitin6, Per Magnus3, 
Stephen Kaptoge2, Emanuele Di Angelantonio2 & David A. Leon1,5,8
Surprisingly few attempts have been made to quantify the simultaneous contribution of well‑
established risk factors to CVD mortality differences between countries. We aimed to develop and 
critically appraise an approach to doing so, applying it to the substantial CVD mortality gap between 
Russia and Norway using survey data in three cities and mortality risks from the Emerging Risk 
Factor Collaboration. We estimated the absolute and relative differences in CVD mortality at ages 
40–69 years between countries attributable to the risk factors, under the counterfactual that the age‑ 
and sex‑specific risk factor profile in Russia was as in Norway, and vice‑versa. Under the counterfactual 
that Russia had the Norwegian risk factor profile, the absolute age‑standardized CVD mortality 
gap would decline by 33.3% (95% CI 25.1–40.1) among men and 22.1% (10.4–31.3) among women. 
In relative terms, the mortality rate ratio (Russia/Norway) would decline from 9–10 to 7–8. Under 
the counterfactual that Norway had the Russian risk factor profile, the mortality gap reduced less. 
Well‑established CVD risk factors account for a third of the male and around a quarter of the female 
CVD mortality gap between Russia and Norway. However, these estimates are based on widely held 
epidemiological assumptions that deserve further scrutiny.
Large mortality differences exist between European countries, and particularly between Russia and Western 
European countries. Despite declines in mortality in Russia from the mid-2000s1, Russian life expectancy is 
still low compared to other countries. For example in 2014 it was 14.8 years shorter among men and 7.6 years 
shorter among women compared to  Norway2. A key component of these differences is the very high mortality 
from cardiovascular disease (CVD) in Russia, particularly at working  ages1,3.
Several attempts have been made to explain the elevated mortality rate in Russia including socioeconomic 
level, standard of medical care, and lifestyle  factors4–7. It is acknowledged that behaviours such as  smoking8,9 
and alcohol  intake10–12 and contextual factors such as gross domestic product (GDP) per  capita13 are likely to 
contribute the elevated mortality rate in Russia.
CVD mortality is one of the most important contributors to mortality dynamics in  Russia14, and it is much 
higher in Russia as compared to other European  countries3, especially in the age group 40–69 years where it is 
8–10 times higher compared to  Norway15. This is likely to be partly explained by higher prevalence of established 
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CVD risk factors. For example, prevalence of smoking remains very high among  men16, and blood pressure levels 
are also high in both men and  women17. In addition, the prevalence of hazardous alcohol drinking in Russia is 
one of the highest  worldwide18.
There have been surprisingly few attempts to systematically examine the potential role of established risk 
factors on CVD mortality patterns between different  countries19. The WHO MONICA  Project20,21 is the most 
well-known attempt to address this issue using consistent methodology across countries. It aimed to explain 
changes in CVD mortality in relation to changes in incidence (risk factor levels) and case-fatality (treatment 
and medical services). It concluded that the established CVD risk factors were unlikely to explain the observed 
CVD mortality differences between the former communist countries and Western Europe between 1984 and 
1986, although no attempt was made to quantify the extent to which the differences between countries could be 
 explained22. More recently, the INTERHEART study quantified the contribution of risk factors to acute (non-
fatal) myocardial infarction within each country, and concluded that established CVD risk factors explained a 
smaller fraction of total myocardial infarction incidence in Eastern Europe than in Western Europe between 
1999 and  200323. An earlier attempt to explain differences in CVD risk between Norway and Russia used data 
from 1987–1995 for Norway and from 1999 from Russia (Arkhangelsk)24. This study found that the population 
average myocardial infarction (fatal and non-fatal) risk score developed by Norway was lower for the Russian 
population than the two studies in Norway. They also found that the average Framingham risk score in Arkhan-
gelsk was roughly the same as the Framingham  average24.
In summary none of these previous studies actually quantified the fraction of differences in CVD mortality 
between populations that was accounted by established risk factors in either absolute or relative terms. Moreover, 
those that looked at Russia or Eastern Europe used data from the 1990s or earlier. In subsequent years CVD 
mortality in Russia has altered dramatically, most recently with substantial falls since  20051.
The objectives of this paper are twofold. First, to quantify for the first time the joint contribution of four well-
established CVD risk factors to the CVD (ischaemic heart disease -IHD- plus stroke) mortality gap between 
Russia and Norway at ages 40–69 years. Second, to identify and critically examine the assumptions underlying 
our approach many of which are common to epidemiological analysis and inference in general.
Results
The means and prevalences of the four risk factors are shown in Table 1 by study. Age-specific summaries are 
presented in Appendix 3. SBP was appreciably higher in Know Your Heart (KYH, (Russia)) than in Tromsø 7 
(Norway) for both men and women. Total cholesterol levels were similar in both studies for men and women 
separately. Smoking prevalence was 2–3 times higher in KYH for men, and only a slight difference of two percent 
points was observed for women. Diabetes prevalence was slightly higher in KYH for both men and women.
CVD mortality rates for Russia and Norway and their alternate mortality rates when applying the counter-
factual risk factor profile from the other country are depicted in Fig. 1 (and Appendix 4). In the counterfactual 
applying the Norwegian risk factor profile to Russia the estimated contributions of established risk factors to 
the excess age-specific CVD mortality in Russia than Norway ranged between 26.7% (ages 65–69) to 48.4% 
(ages 40–44) among men, and between 18.6% (ages 60–64) to 36.8% (ages 40–44) among women (Table 2, 
and Appendix 5 for IHD and stroke results). Overall, the absolute age-standardized CVD mortality gap would 
decline by 33.3% among men and 22.1% among women in this counter-factual scenario. In relative terms, the 
age-standardized mortality rate ratio (MRR, Russia/Norway) would decline from 10.0 to 7.0 among men and 
from 9.0 to 7.3 among women (Table 2). Conversely, in the counterfactual assuming Russian risk factor profile 
in Norway the observed results were in the same direction (identical MRR), but the impact was lower in absolute 
terms (ranging between 2.2 and 8.8%).
Discussion
This study used contemporary CVD risk models to quantify the risk factor contribution to the CVD (IHD plus 
stroke) mortality gap between two countries. To our knowledge this is the first attempt to quantify in relative 
and absolute terms the contribution of a combination of specific risk factors to differences in mortality from 
CVD between two countries. We found that well-established CVD risk factors (SBP, total cholesterol, smok-
ing and diabetes) appear to account for about a third of the absolute CVD mortality gap between Russia and 
Norway among men, and around a quarter among women. The relatively low proportion of the gap explained 
by these risk factors is in line with other  investigations24 including the MONICA study’s attempt to both explain 
Table 1.  Study specific age-standardized risk factor means (systolic blood pressure and total cholesterol) and 
prevalences (smoking and diabetes) with 95% confidence intervals. SBP systolic blood pressure. *Age-specific 
estimates can be found in Appendix 3.
Data SBP (mmHg) Cholesterol (mmol) Smoking (%) Diabetes (%)
Men
Know your heart (Russia) 137.4 (136.5–138.4) 5.4 (5.3–5.5) 37.5% (35.0–39.9) 6.5% (5.3–7.7)
Tromsø 7 (Norway) 130.8 (130.5–131.2) 5.5 (5.4–5.5) 13.7% (12.9–14.4) 5.2% (4.7–5.7)
p-value for difference  < 0.001 0.025  < 0.001 0.055
Women
Know your heart (Russia) 128.6 (127.8–129.4) 5.7 (5.6–5.7) 17.2% (15.6–18.9) 8.2% (7.1–9.3)
Tromsø 7 (Norway) 123.4 (123.1–123.8) 5.5 (5.5–5.6) 15.3% (14.5–16.0) 4.0% (3.6–4.4)
p-value for difference  < 0.001  < 0.001 0.038  < 0.001
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international variation in CVD mortality cross-sectionally22,25 as well as trends over time in countries based on 
data on smoking, blood pressure and  cholesterol20,21.
There are a number of potential explanations as to why these well-established risk factors only explain a small 
part of the CVD mortality gap. The most obvious of these is that there are other key determinants of cardiovas-
cular mortality differences between countries that are in addition to smoking, blood pressure, cholesterol and 
diabetes. These include both other risk factors such as heavy and harmful alcohol consumption, exposure to 
particulate air pollution and differences in standard of primary and secondary prevention of CVD events and 
mortality through treatment.
Figure 1.  CVD mortality rates in Russia, Norway, Russia assuming the Norwegian risk factor profile (Russia 
counterfactual) and Norway assuming the Russian risk factor profile (Norway counterfactual).
Table 2.  Contribution of risk factors to the CVD mortality gap between Russia and Norway in absolute terms 
(%) and in relative terms (mortality risk ratios (MRR)). 95% uncertainty intervals denoted within brackets. 
Standard population: Russia 2014 (Human Mortality Database). Russia’ Russia assuming Norwegian risk factor 
prevalence, Norway’ Norway assuming Russian risk factor prevalence.
Age MRR (Russia/Norway) % Gap explained, Russia’
% gap explained, 
Norway’ Counterfactual MRR
Men
40–44 9.7 48.4 (44.4–52.1) 8.8 (7.6–10.1) 5.5 (5.2–5.8)
45–49 12.7 36.9 (34.1–39.7) 4.4 (3.9–4.9) 8.4 (8.1–8.7)
50–54 9.2 32.0 (29.5–34.3) 4.9 (4.3–5.4) 6.6 (6.4–6.8)
55–59 10.1 37.4 (35.6–39.3) 5.6 (5.2–6.0) 6.7 (6.5–6.8)
60–64 10.0 35.0 (33.4–36.8) 5.1 (4.8–5.5) 6.8 (6.7–7.0)
65–69 9.8 26.7 (24.9–28.4) 3.6 (3.3–3.9) 7.5 (7.3–7.6)
Age-standardized 10.0 33.3 (31.4–35.3) 4.8 (4.4–5.3) 7.0 (6.8–7.1)
Women
40–44 7.9 36.8 (30.4–43.0) 6.8 (5.2–8.7) 5.4 (5.0–5.8)
45–49 8.3 25.9 (21.2–30.2) 4.0 (3.1–5.0) 6.4 (6.1–6.7)
50–54 6.9 27.4 (24.7–30.1) 5.1 (4.5–5.8) 5.3 (5.2–5.5)
55–59 7.7 18.6 (15.5–21.8) 2.9 (2.3–3.5) 6.4 (6.2–6.6)
60–64 11.1 19.8 (15.9–23.6) 2.2 (1.7–2.7) 9.1 (8.7–9.5)
65–69 9.4 22.8 (19.6–26.3) 3.0 (2.5–3.6) 7.5 (7.2–7.8)
Age-standardized 9.0 22.1 (18.7–25.7) 3.1 (2.5–3.7) 7.3 (7.0–7.5)
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Furthermore, there are two assumptions that deserve examination whose significance goes beyond this par-
ticular attempt to explain international differences. This is the extent to which the associations between the CVD 
risk factors and mortality are generalizable across populations and how far their combined influence on mortality 
risk really is best estimated on a multiplicative scale.
We did not include alcohol as one of the risk factors, despite the fact that harmful and episodic drinking is a 
risk factor and is prevalent in Russia where it has been associated with increased CVD  risk26,27. The estimation 
of its impact to CVD mortality is complex and  multidimensional28, especially in a context of high prevalence 
of binge drinking as is found in  Russia10,11. Despite its importance we must recognize that alcohol is closely 
correlated with the conventional CVD risk factors included in our study such as smoking and blood  pressure29, 
and the only attempt including alcohol in fatal atherosclerotic CVD risk prediction algorithms in Central and 
Eastern Europe failed to improve their  performance30. Furthermore, as the relationship between alcohol and CVD 
in Russia is different than elsewhere and singularly  complex10 we did not think it was reasonable to extrapolate 
from ERFC-derived alcohol-associated relative  risks28.
Several other risk factors of potential importance were not included. For example, levels of salt intake in the 
diet may well vary between Russia and Norway. However, the assumption is that its effect on CVD mortality is 
largely going to be through its impact on blood pressure—which we did include, thus making this exclusion less 
problematic. Another relevant factor is particulate air pollution, which has also been linked to CVD events and 
 mortality31,32, with levels of pollution being appreciably higher in Russia than in  Norway33.
One potential explanation of the differences in risk that should be mentioned are genetic differences between 
the populations studied. It should be noted however, that the urban populations of Arkhangelsk and Novosibirsk 
are largely ethnic Russians, whose genetic ancestry overlaps substantially with that of Northern  Europeans34. 
Nevertheless, a classic way to assess the potential contribution of genes vs environment is to undertake a study 
of  migrants35. This would compare the mortality risks among Russians living in countries with much lower CVD 
risks. There are unfortunately very few such studies. In a study of migrants who moved (1990–2003) from the 
former Soviet Union to Israel Ott et al. found that their CVD mortality was one third of that of the population of 
the Russian  Federation36. However, this study of recent first-generation migrants provides only some superficial 
insight into the importance or otherwise of environmental factors. Migrants in general are a special group of 
their country of origin, and will bring with them aspects of their lifestyles particularly if they migrate in adult life.
Overall, however, genetics is unlikely to explain much if any of the current differences in CVD mortality 
between Russia and Norway (and other Western European countries) for two other reasons. As already noted, 
CVD mortality in Russia has been falling very steeply since 2005, and the gap with Norway is closing. These 
major falls cannot be explained by genetics. Looking further back however in the 1960s CVD mortality in Russia 
was very similar to that in Western European countries such as the UK, Sweden and France in the  1960s1. It was 
only in the 1970s and 1980s that a large divergence arose.
One of the key factors that may contribute to CVD mortality differences is the effective treatment and medi-
cal prevention of CVD. There is evidence for example, that since 2010 there has been a reduction of in hospital 
mortality from myocardial infarction, most likely related to a very rapid expansion of percutaneous coronary 
intervention facilities across  Russia7,37. Moreover, more effective and longer term control of blood pressure in 
the Norwegian population, and the irregular control of it in  Russia38 may also be a relevant factor that is not 
reflected in the mean blood pressures per se. Not factoring in differences in standard of health care between 
Russia and Norway may account for some of the residual differences in mortality between Russia and Norway 
once the effects of the four risk factors are accounted for. At this more general level, Russia has a disadvantage 
as compared to Norway in other important socioeconomic determinants, for example in GDP per capita or 
in inequalities within each population. Socioeconomic differences and inequalities may explain some of the 
elevated risk factors  profiles39, and it has been found that life expectancy in Russia is below that expected given 
its moderately high  GDP13.
Beyond these potential explanations for the failure of the risk factors to explain the mortality gap, meas-
urement error in exposures may contribute, including the use of single cross-sectional measures rather than 
longitudinal exposure profiles.
This study used measured (SBP and total cholesterol) and self-reported (diabetes and smoking) data collected 
in two cities in Russia and one in Norway. Efforts were made to accurately collect those data in comparable ways. 
A calibration study of biomarkers showed very small cross-laboratory differences in total cholesterol measure-
ments between the two  populations40, which made no substantial difference to our results. Furthermore, we need 
to acknowledge that our risk factor profiles come from three cities (two in Russia and one in Norway) and are 
not based on nationally representative samples. Nevertheless CVD mortality rates in Tromsø are rather similar 
to those for Norway as a whole, as are CVD mortality rates in Novosibirsk and Arkhangelsk similar to those in 
Russia as a  whole15. The participation rate in KYH was 48%, although the educational profile as the participants 
was similar to that of the cities from which they  came15. Moreover, the risk factor data is consistent with what 
previously observed, including smoking and blood pressure  levels41,42. In the Tromsø Study the participation 
rate was 65% and risk factor prevalences we used from the Tromsø Study are comparable those from the HUNT 
Study in the county of Nord-Trøndelag,  Norway43,44.
Ideally, instead of cross-sectional data, it would have been better to use life-course data from cohort stud-
ies within each country as longitudinal measures of exposures have been found to be more relevant for CVD 
mortality prediction for various behavioural  factors45. However, directly comparable data of this type are not 
available. The fact that even nowadays important differences in risk factor profiles exist (e.g. higher blood pressure 
levels among Russians compared to Norwegians or three-fold higher smoking prevalence among Russian men 
compared to their Norwegian counterparts (see Table 1)) suggests that, despite narrowing the gap, the Russian 
CVD mortality disadvantage could persist for decades.
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Our central information on the mortality risks associated with risk factor profiles were derived from 85 
cohort studies from the ERFC. In using these estimates, we have assumed that the combined effect on mortality 
of different combinations of risk factors is multiplicative, with no interaction on the ratio scale. In other words, 
that the hazard ratios for one factor are independent of the level of every other risk factor, with the one excep-
tion of age. There is however some evidence from two different large pooled analyses that suggest the existence 
of quantitative and qualitative interactions between SBP and cholesterol on the risk of IHD and  stroke46,47. If 
there are interactions on a multiplicative scale this would undermine the estimates we have made of the fraction 
of mortality accounted for by the four risk factors considered, although the magnitude and direction of bias 
are unclear. Testing the extent to which an interaction between risk factors could improve the estimates of joint 
effects on mortality should be a priority in large epidemiological studies and could aid improving comparative 
risk assessment estimates.
A second fundamental assumption we have made, which is also made throughout much of CVD epidemiol-
ogy in general is that within a multiplicative framework, the association of each risk factor and mortality risk is 
the same across  populations48. However, due to the paucity of large-scale follow-up studies of CVD risk factors 
in Russia relatively little work has been done to investigate how far CVD risk factors show a similar strength of 
association in Russia compared to other countries. What is known is that the association of alcohol on CVD 
mortality in Russia is not the same as elsewhere, a fact that has been incorporated into estimates of alcohol 
attributable mortality globally by  WHO18.
The absolute difference in mortality explained differs according to the counterfactual used. This is because 
the effect on absolute mortality risk of applying any risk profile to a low baseline mortality group will be neces-
sarily smaller than applying the same profile to a high mortality baseline group. In our case, the baseline group 
consist of individuals who are non-smokers, do not have diabetes and have optimal levels of blood pressure and 
cholesterol. Hence, the lack of symmetry between the two counterfactual estimates. Indeed, we show that the 
mortality rates in the “optimal” baseline group for Russia and Norway using the same methodology are appreci-
ably lower than that in Russia (Appendix 6). These differences are largely going to reflect differences in levels 
of other risk factors as well as the impact of differences in standard of primary and secondary CVD prevention 
through the health sector.
The question as to which counterfactual best summarises the contribution of our four CVD risk factors to 
mortality differences is debateable. However, a priori the assumption is that the risk profile in Norway is more 
favourable as CVD mortality rates are so much lower than in Russia. Therefore, we focused the discussion based 
on the estimates provided by the counterfactual for which the Norwegian risk factor profile is applied to Russia.
In conclusion, our analyses suggest that the four well-established CVD risk factors analysed account for no 
more than a third of the CVD mortality gap between Russia and Norway. Our methodological extension using 
multivariable adjusted hazard ratios for multiple risk factors allowed us to provide, for the first time, estimates 
on the joint contribution of well-established CVD risk factors to CVD mortality differences between Russian and 
Norwegian contexts. Our careful consideration of the assumptions that need to be made in order to estimate the 
joint and simultaneous contribution of key risk factors to explaining mortality differences between populations 
illustrates the challenge that is faced in this area. In reality, the best estimates would be those based on large-
scale cohort studies with comparable protocols. More broadly many of these assumptions are common to much 
epidemiological analysis and yet their validity on closer inspection has not been demonstrated. A more critical 
approach to these is a priority. These include the widely held assumptions that hazard ratios for CVD risk factors 
are generalizable across populations and that risks combine multiplicatively.
Methods
Data. We used three sources of information: (i) risk factor levels from recent population-based surveys car-
ried out in two cities in Russia (Arkhangelsk and Novosibirsk, the Know Your Heart study, 2015–2018) and 
in one Norwegian city, Tromsø (Tromsø Study seventh survey, 2015–2016); (ii) mutually adjusted risk factor 
hazard ratios for CVD mortality from the WHO CVD risk prediction models based on pooled analyses of data 
from 85 cohort  studies48; and (iii) contemporary observed national CVD mortality rates for Russia and Norway 
(2016).
Risk factor prevalence and levels were obtained from population-based cross-sectional surveys in Russia and 
Norway that jointly constitute the Heart to Heart  collaboration15. For Russia we used information from the Know 
Your Heart (KYH) study (2015–2018), a cross-sectional survey carried out in two Russian cities (Arkhangelsk and 
Novosibirsk)15. For Norway we used data from the 7th wave of the Tromsø Study (Tromsø 7)49,50 (2015–2016). 
The risk factors included in the analysis were age (years), sex (male/female), systolic blood pressure (SBP, mmHg), 
total cholesterol (mmol/L), smoking (yes/no), and diabetes (yes/no). SBP and total cholesterol were measured, 
whereas diabetes and smoking where self-reported using similar approaches in the two studies (Appendix 1). 
Tromsø 7 had a participation rate of 66%, whereas KYH had a participation rate of 48%. The analysis included 
participants with complete data on all the relevant variables (3605 (86.8%) of 4153 participants in KYH, and 
16,803 (95.2%) of 17,650 participants in Tromsø 7).
Data on the population age- and sex-specific mortality from ischaemic heart disease (IHD; ICD10: I20-I25) 
and stroke (I60–I69, G45) were retrieved from the Human Cause-of-Death database for Russia (2016) and from 
the WHO Mortality Database for Norway (2016).
Analyses. Mutually adjusted sex-specific hazard ratios for mortality due to IHD and stroke were obtained 
from pooled analyses of population-based cohort data in the Emerging Risk Factors Collaboration (ERFC) 
adopting methods previously used in the derivation of the WHO CVD risk prediction  models48. These models 
included the predictor variables: age, SBP, total cholesterol, smoking, diabetes and their interactions with  age48,51 
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and hazard ratios were calculated using Cox proportional hazard regression model with duration (i.e. time from 
entry into the study) as the time scale. Appendix 2 details hazard ratios for the risk factor associations with IHD 
and stroke mortality. Deviation from the proportional hazards assumption was either minimal or non-existent, 
assessed by fitting models including time-varying covariates.
The estimation of the joint risk factor contribution to CVD mortality differences between Russia and Norway 
was done in several successive steps. First, for each individual in the Russian and Norwegian dataset we calcu-
lated their predicted mortality risks relative to the multidimensional baseline category using the WHO model 
coefficients. Secondly, for each sex, 5-year age group and CVD cause we calculated the mean values of these 
predicted risks in each study to estimate the predicted relative mortality hazard in Russia (RUS) and in Norway 
(NOR). The ratio of these predictive relative mortality hazards between studies (e.g. RUS/NOR) was taken as 
an estimate of the proportional change in CVD mortality that would occur if the risk factor distribution in the 
one population was counterfactually assumed to apply to the other. Thus, for example, for a particular sex, age 
group and CVD cause RUS/NOR is the proportional change in mortality hazard that would occur in Norway if 
this country had the counterfactual risk factor distribution seen in Russia for this particular age- and sex-group 
combination. The reciprocal (NOR /RUS) gives the equivalent proportional change in Russia that would occur if 
they had the counterfactual risk factor distribution of Norway. To generate uncertainty ranges we used the vector 
of point estimates and their variance–covariance matrix to make 1,000 random draws of the log hazard ratios 
from a multivariate normal distribution. We then used these drawn coefficient estimates to re-estimate the relative 
mortality hazards between studies, and considered the 2.5th and 97.5th centiles of the resulting distributions to 
be estimates of uncertainty ranges for the estimated counterfactual mortality rates ratios.
The absolute counterfactual cause-specific CVD mortality rate in each population (country, age, sex) was then 
estimated by multiplying the appropriate ratio by the corresponding observed mortality rate.
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